Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Zirabev [legacy through FY23] by Quarter
Zirabev (bevacizumab biosimilar) [legacy through FY23] — International operational (constant-currency) YoY (%) (%)
Pfizer Zirabev [legacy through FY23]: -32.0% in Q4 2023, down 16.0 pts from a year earlier. That is the lowest of the 9 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
“|| Zirabev | 88 | 130 | (32%) | (32%) | 66 | 97 | (31%) | 22 | 33 | (34%) | (32%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Zirabev [legacy through FY23] (%), quarterly Q3 2021–Q4 2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/zirabev-leg-oper-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.